Skoči na glavni sadržaj

Gynaecologia et perinatologia : : časopis za ginekologiju, perinatologiju, reproduktivnu medicinu i ultrazvučnu dijagnostiku, Vol. 20 No. 1, 2011.

Pregledni rad

PHARMACOLOGICAL COST-BENEFIT ANALYSIS OF VACCINATION OF ADOLESCENTS BY CERVARIX

Ante Ćorušić ; Klinika za ženske bolesti i porode KBC-a i Medicinskog Fakulteta Sveučilišta u Zagrebu, Petrova 13, Zagreb
Magdalena Karadža ; Klinika za ženske bolesti i porode KBC-a i Medicinskog Fakulteta Sveučilišta u Zagrebu, Petrova 13, Zagreb
Pavo Planinić ; Klinika za ženske bolesti i porode KBC-a i Medicinskog Fakulteta Sveučilišta u Zagrebu, Petrova 13, Zagreb
Lana Škrgatić ; Klinika za ženske bolesti i porode KBC-a i Medicinskog Fakulteta Sveučilišta u Zagrebu, Petrova 13, Zagreb
Dragana Ljubojević-Grgec ; Poliklinika za ginekologiju, opstetriciju, dermatologiju i venerologiju »Ginoderma«, Zagreb
Josip Juras ; Klinika za ženske bolesti i porode KBC-a i Medicinskog Fakulteta Sveučilišta u Zagrebu, Petrova 13, Zagreb
Jozo Blajić ; Klinika za ženske bolesti i porode KBC-a i Medicinskog Fakulteta Sveučilišta u Zagrebu, Petrova 13, Zagreb

Puni tekst: hrvatski pdf 139 Kb

str. 21-29

preuzimanja: 1.170

citiraj

Sažetak

Cervical carcinoma is the second most fequent female carcinoma in the world. In Croatia it took the 8th place. Cervical intraepithelial neoplasms and cervical carcinoma are related to permanent infection caused by high oncogenic type of HPV. The cost of treatment and therapy depends on grade of disease. In multinational double blinded randomised studies Cervarix vaccine has demonstrated its high efficiency in production of circulating serum antibodies, and the decrement of prevalence of HPV infection, preinvasive lesions and cervical carcinoma when applied in sexually not active adolescents. Cervarix vaccine also decreases the prevalence of permanent infections caused by HPV in sexually active women. Using mathematical models and considering high vaccine efficiency, it is predicted decrease of morbidity and mortality due to cervical carcinoma by 60–75%. When direct and indirect costs of therapy of cervical carcinoma and life quality were compared to cost of vaccination by Cervarix, it could be saved more than 50 milions of kunas in Croatia annually.

Ključne riječi

uterine cervix dysplasias; prophylaxis; vaccination

Hrčak ID:

69975

URI

https://hrcak.srce.hr/69975

Datum izdavanja:

1.3.2011.

Podaci na drugim jezicima: hrvatski

Posjeta: 2.756 *